The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.
The five-year grant will support optimizing the use of polymyxin B to treat Gram-negative bacterial infections and identify protein biomarkers of drug-associated toxicity.
The researchers will use the expressed proteins to refine and optimize multiple-reaction monitoring assays that they will then apply to actual biological samples.
The partners will combine the sciFlexarrayer with Anteo's reagents to improve the functionality and shelf-life of activated glass and polymer slides and other arrays.
Stanford researchers used Fluidigm's CyTOF instrument to explore links between the diversity of natural killer (NK) cell populations and HIV susceptibility.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.